ATE347906T1 - Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen - Google Patents

Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen

Info

Publication number
ATE347906T1
ATE347906T1 AT99967388T AT99967388T ATE347906T1 AT E347906 T1 ATE347906 T1 AT E347906T1 AT 99967388 T AT99967388 T AT 99967388T AT 99967388 T AT99967388 T AT 99967388T AT E347906 T1 ATE347906 T1 AT E347906T1
Authority
AT
Austria
Prior art keywords
ultrafiltration
ammonium sulfate
polysaccharide
purification
protein conjugate
Prior art date
Application number
AT99967388T
Other languages
English (en)
Inventor
Ronald P Mcmaster
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Application granted granted Critical
Publication of ATE347906T1 publication Critical patent/ATE347906T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99967388T 1998-12-29 1999-12-16 Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen ATE347906T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/221,728 US6146902A (en) 1998-12-29 1998-12-29 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions

Publications (1)

Publication Number Publication Date
ATE347906T1 true ATE347906T1 (de) 2007-01-15

Family

ID=22829099

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06025470T ATE496633T1 (de) 1998-12-29 1999-12-16 Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen
AT99967388T ATE347906T1 (de) 1998-12-29 1999-12-16 Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06025470T ATE496633T1 (de) 1998-12-29 1999-12-16 Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen

Country Status (12)

Country Link
US (1) US6146902A (de)
EP (3) EP1762245B1 (de)
AT (2) ATE496633T1 (de)
AU (1) AU2367500A (de)
CA (2) CA2358022C (de)
CY (3) CY1105985T1 (de)
DE (3) DE69943169D1 (de)
DK (2) DK1140156T3 (de)
ES (2) ES2278551T3 (de)
HK (1) HK1106999A1 (de)
PT (2) PT1762245E (de)
WO (1) WO2000038711A2 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
EP1946769B1 (de) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalente Impfstoffzusammensetzung mit niedriger Dose von Haemophilus influenzae Typ B
CA2426246A1 (en) * 2000-10-18 2002-04-25 Clarity Technologies Incorporated Method and device for diluting a fluid and detecting analytes within a diluted fluid
PL226184B1 (pl) 2001-01-23 2017-06-30 Aventis Pasteur Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko
EP1373491B1 (de) 2001-04-04 2015-12-30 DSM IP Assets B.V. Gereinigte lactase
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2172213B1 (de) 2003-01-30 2013-04-03 Novartis AG Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
CA2524853A1 (en) 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
WO2004103400A2 (en) 2003-05-07 2004-12-02 Aventis Pasteur,Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
WO2005000345A2 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
BRPI0411815A (pt) * 2003-06-23 2006-08-08 Baxter Int vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
PL1961426T3 (pl) 2003-10-02 2012-03-30 Gsk Vaccines S R L Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
US20050169941A1 (en) * 2004-01-29 2005-08-04 Andrew Lees Use of amino-oxy functional groups in the preparation of protein-polysaccharide conjugate vaccines
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
CN101934077A (zh) * 2004-08-30 2011-01-05 圣诺菲·帕斯图尔公司 多价的脑膜炎球菌产生的多糖-蛋白质偶联物和疫苗
CN101072586A (zh) * 2004-09-21 2007-11-14 圣诺菲·帕斯图尔公司 多价脑膜炎球菌源性多糖－蛋白质缀合物及疫苗
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
ES2670231T3 (es) * 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. Regímenes para inmunización con conjugados meningocócicos
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
PL2066344T3 (pl) 2006-09-07 2011-10-31 Glaxosmithkline Biologicals Sa Skojarzona szczepionka zawierająca inaktywowany wirus polio
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2436700B8 (de) * 2007-03-23 2018-08-01 Wyeth LLC Verkürztes reinigungsverfahren für die herstellung von streptococcus pneumoniae-kapselpolysacchariden
BRPI0810778A2 (pt) 2007-05-02 2011-09-13 Glaxosmithkline Biolog Sa kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5689064B2 (ja) 2008-10-27 2015-03-25 ノバルティス アーゲー 精製方法
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2385981B1 (de) * 2008-12-18 2019-09-04 Wyeth LLC Verfahren zur kontrolle des molekulargewichts von streptococcus pneumoniae-polysacchariden unter verwendung von kohlenstoff
MX2011006432A (es) * 2008-12-18 2011-09-29 Wyeth Llc Metodo para controlar el peso molecular del polisacarido streptococcus pneumoniae serotipo 19a.
NZ597191A (en) 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
RS56000B1 (sr) 2009-10-30 2017-09-29 Glaxosmithkline Biologicals Sa Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
EP2496941B1 (de) 2009-11-04 2016-07-13 Thomas M. Buchanan Verfahren und vorrichtungen zur erhöhung der empfindlichkeit und zur bewertung der probeneignung und der reagenzienreaktivität in immunassays mit schnellem lateralfluss
US9044517B2 (en) 2009-12-17 2015-06-02 Fina Biosolutions, Llc Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
DK2560738T3 (da) 2010-04-23 2019-08-26 Serum Inst India Ltd Simpel fremgangsmåde til samtidig fjernelse af flere urenheder fra dyrkningssupernatanter til ultralave niveauer
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
US10124051B2 (en) 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
EP2903650B1 (de) 2012-10-02 2018-04-04 GlaxoSmithKline Biologicals SA Nichtlineare saccharidkonjugate
ES2848048T3 (es) 2012-10-03 2021-08-05 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN104387491B (zh) * 2014-11-25 2017-12-05 中国医学科学院医学生物学研究所 一种b型流感嗜血杆菌荚膜多糖的制备方法
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
CA3033364A1 (en) 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
WO2018067582A2 (en) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide immunogens and their use
US11202824B2 (en) 2016-10-31 2021-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
FI3678654T3 (fi) 2017-09-07 2024-09-02 Merck Sharp & Dohme Llc Pneumokokkipolysakkaridit ja niiden käyttö immunogeenisissä polysakkaridi-kantajaproteiini-konjugaateissa
CN117982633A (zh) 2017-12-06 2024-05-07 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
WO2019212844A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
EP3787673A4 (de) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. Verfahren zur herstellung von kapsulären streptococcus-pneumoniae-polysaccharid-trägerproteinkonjugaten
WO2020061564A1 (en) 2018-09-23 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
SG11202106541WA (en) 2018-12-19 2021-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CN113966234A (zh) 2019-05-10 2022-01-21 葛兰素史克生物有限公司 缀合物的产生
CN115803050A (zh) 2020-06-12 2023-03-14 葛兰素史克生物有限公司 使用纳米颗粒疫苗的细菌免疫
CA3201450A1 (en) 2020-11-13 2022-05-19 Glaxosmithkline Biologicals Sa Bacterial protein carriers and conjugation methods
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022182388A1 (en) * 2021-02-26 2022-09-01 The Penn State Research Foundation Separation apparatus and method
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
WO2023200704A1 (en) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Protein-saccharide conjugation with sodium cyanoborohydride

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4456691A (en) * 1983-02-28 1984-06-26 Suad Stark Antigen for PCB, antibody raised by same, and method of making same
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4780409A (en) * 1985-05-02 1988-10-25 Genetic Systems Corporation Thermally induced phase separation immunoassay
JPH0643336B2 (ja) * 1988-06-30 1994-06-08 呉羽化学工業株式会社 血管増殖抑制剤
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
AU1140495A (en) * 1994-01-27 1995-08-03 Bristol-Myers Squibb Company Method for preparing thioether conjugates
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules

Also Published As

Publication number Publication date
PT1140156E (pt) 2007-02-28
ES2277462T3 (es) 2007-07-01
EP2292261A1 (de) 2011-03-09
ATE496633T1 (de) 2011-02-15
DE69943169D1 (de) 2011-03-10
CA2358022A1 (en) 2000-07-06
CY1105985T1 (el) 2011-04-06
DE69934434T2 (de) 2008-01-03
EP1140156B1 (de) 2006-12-13
HK1106999A1 (en) 2008-03-28
US6146902A (en) 2000-11-14
EP1762245B1 (de) 2011-01-26
WO2000038711A2 (en) 2000-07-06
AU2367500A (en) 2000-07-31
CY1111375T1 (el) 2015-08-05
DE06025470T1 (de) 2007-08-02
CA2358022C (en) 2008-03-11
CY2200152T2 (el) 2010-07-28
EP1140156A2 (de) 2001-10-10
DK1140156T3 (da) 2007-03-26
CA2621097A1 (en) 2000-07-06
PT1762245E (pt) 2011-05-02
DK1762245T3 (da) 2011-04-04
WO2000038711A3 (en) 2000-10-19
ES2278551T1 (es) 2007-08-16
DE69934434D1 (de) 2007-01-25
ES2278551T3 (es) 2011-04-11
EP1762245A2 (de) 2007-03-14
EP1762245A3 (de) 2007-04-25

Similar Documents

Publication Publication Date Title
ATE496633T1 (de) Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
DK0665013T3 (da) Behandling af hyperproliferative karsygdomme
ATE321146T1 (de) Methoden zur modifikation von kohlenhydratanteilen
DE59100581D1 (de) Verfahren zur herstellung von torfersatz, anlage zur durchführung dieses verfahrens, anwendung des verfahrens und nach diesem verfahren hergestellter torfersatz.
MXPA04001224A (es) Agentes para incrementar la respuesta inmune.
DE69534120D1 (de) Topisch anzuwendende ketoconazol enthaltende emulsionen
DE60026844D1 (de) Verfahren zur herstellung von 3,3-dimethylbutanal
ATE288758T1 (de) Verfahren zur herstellung von polymorphen des clarithromycins
DK0528494T3 (da) Katalysatorsammensætninger omfattende en modificeret zeolit af Y-typen
ATE321775T1 (de) Reinigung von fibrinogen aus milch durch den einsatz von kationenaustauschchromatographie
DE60101575D1 (de) Verfahren zur herstellung von pharmazeutisch annehmbaren salzen des (ss,rs)-s-adenosyl-l-menthionin
FI973469A0 (fi) Menetelmä tekijän IX valmistamiseksi biologisista lähteistä
DE69421609D1 (de) Hypochloritbleichmittelzusammensetzungen
ATE275149T1 (de) Verfahren zur herstellung von taxanderivaten
BR0016668A (pt) Processo para a preparação de n-fosfonometilglicina, processo para a preparação de um composto fosfono, composto fosfono, e, intermediário
DE59104649D1 (de) Verfahren zur Herstellung von N,N,N',N'-Tetraglycidyl-3,3'-dialkyl-4,4'-diaminodiphenylmethanen.
ATE291569T1 (de) Verfahren zur herstellung von dnda
DE59801815D1 (de) Verfahren zur herstellung von 1,2-dichlorethan durch oxichlorierung
ATE213734T1 (de) Verfahren zur herstellung von 1,3- disubstituierten 2-nitroguanidinen
BR0007960A (pt) Tablete detergente revestido
DK0892810T3 (da) Krystallisation af et protein med et svovlsalt
DE60001225D1 (de) Verfahren zur herstellung von epipodophyllotoxine-4'-demethyl-4'-phosphat-2",3"-bis pentafluorphenoxyacetyl-4",6"-ethyliden- beta-d-glucosid und seine salzen
ATE250620T1 (de) Verfahren zur herstellung von etoposid
BR0002329B1 (pt) processo de tratamento de efluente papeleiro kraft e1 pelo sistema de enzima-mediador: lacase-hidroxamatos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140156

Country of ref document: EP